nach oben

International Journal of Clinical Oncology

Erschienen in:

01.02.2013 | Original Article

Difference in survival and prognostic factors between smokers and never-smokers with advanced non-small-cell lung cancer

verfasst von: Shiro Tanaka, Kazuhiro Yanagihara, Satoshi Tamaru, Satoshi Teramukai, Toshiyuki Kitano, Masanori Fukushima

Erschienen in: International Journal of Clinical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Our aims were to investigate whether the association between smoking and survival is significant when adjusted for prognostic factors including use of epidermal growth factor tyrosine kinase inhibitors and the Glasgow Prognostic Score, an established score for inflammation, and to explore prognostic factors.

Methods

We analyzed 244 patients with stage IIIB or IV non-small-cell lung cancer in a registry, including only chemotherapy-receiving outpatients with performance status zero.

Results

Of 244 patients, 170 had died and the median follow-up time for the 74 surviving patients was 12.0 months. In multivariate Cox regression, smoker (hazard ratio compared to never-smoker: 1.67, P < 0.01), stage IV (hazard ratio compared to IIIB: 1.72, P < 0.01), and elevated C-reactive protein level (hazard ratio per 1 mg/dL increase: 1.08, P < 0.01) were significantly associated with shorter survival. The association between survival and smoking was significant, even after adjustment for the Glasgow Prognostic Score and regimens of chemotherapy (hazard ratio: 1.72, P = 0.02). In never-smokers, increased neutrophils were a major determinant of shorter survival and the interaction test between smoking and neutrophils was significant (hazard ratio per 1,000/mm³ increase for smokers: 1.01; hazard ratio per 1,000/mm³ increase for never-smokers: 1.44, P for interaction <0.01).

Conclusions

Known factors including treatment response or inflammatory process are not responsible for the fact that advanced non-small-cell lung cancer patients without any history of smoking have better survival than those who have smoked.

Chen CJ, Wu HY, Chuang YC et al (1990) Epidemiologic characteristics and multiple risk factors of lung cancer in Taiwan. Anticancer Res 10:971–976PubMed

Toh CK, Gao F, Lim WT et al (2006) Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 20:2245–2251CrossRef

Wakelee HA, Chang ET, Gomez SL et al (2007) Lung cancer incidence in never smokers. J Clin Oncol 25:472–478PubMedCrossRef

Sun S, Schiller JH, Gazdar AF (2007) Lung cancer in never smokers—a different disease. Nat Rev Cancer 7:778–7790PubMedCrossRef

Subramanian J, Govindan R (2007) Lung cancer in never smokers: a review. J Clin Oncol 10:561–570CrossRef

Fujisawa T, Iizasa T, Saitoh Y et al (1999) Smoking before surgery predicts poor long-term survival in patients with stage I non-small-cell lung carcinomas. J Clin Oncol 17:2086–2091PubMed

Tammemagi CM, Neslund-Dudas C, Simoff M et al (2004) Smoking and lung cancer survival: the role of comorbidity and treatment. Chest 125:27–37PubMedCrossRef

Nordquist LT, Simon GR, Cantor A et al (2004) Improved survival in never-smokers versus current smokers with primary adenocarcinoma of the lung. Chest 126:347–351PubMedCrossRef

Toh CK, Wong EH, Lim WT et al (2004) The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis. Chest 126:1750–1756PubMedCrossRef

10.

Kawai H, Tada A, Kawahara M et al (2005) Smoking history before surgery and prognosis in patients with stage IA non-small-cell lung cancer-a multicenter study. Lung Cancer 49:63–70PubMedCrossRef

11.

Tsao AS, Liu D, Lee JJ et al (2006) Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 106:2428–2436PubMedCrossRef

12.

Zhou W, Heist RS, Liu G et al (2006) Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients. Lung Cancer 53:375–380PubMedCrossRef

13.

Bryant A, Cerfolio RJ (2007) Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest 132:185–192PubMedCrossRef

14.

Subramanian J, Velcheti V, Gao F et al (2007) Presentation and stage-specific outcomes of lifelong never-smokers with non-small cell lung cancer (NSCLC). J Thorac Oncol 2:827–830PubMedCrossRef

15.

Itaya T, Yamaoto N, Ando M et al (2007) Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer. Cancer Sci 98:226–230PubMedCrossRef

16.

Hanagiri T, Sugio K, Mizukami M et al (2008) Significance of smoking as a postoperative prognostic factor in patients with non-small cell lung cancer. J Thorac Oncol 3:1127–1132PubMedCrossRef

17.

Guo NL, Tosun K, Horn K (2009) Impact and interactions between smoking and traditional prognostic factors in lung cancer progression. Lung Cancer 66:386–392PubMedCrossRef

18.

Teramukai S, Kitano T, Kishida Y et al (2009) Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer 45:1950–1958PubMedCrossRef

19.

Shepherd FA, Dancey J, Ramlau R et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132PubMedCrossRef

20.

Thatcher N, Chang A, Parikh P et al (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527–1537PubMedCrossRef

21.

Zhang Z, Xu F, Wang S et al (2008) Influence of smoking on histologic type and the efficacy of adjuvant chemotherapy in resected non-small cell lung cancer. Lung Cancer 60:434–440PubMedCrossRef

22.

Yanbaeva DG, Dentener MA, Creutzberg EC et al (2007) Systemic effects of smoking. Chest 131:1557–1566PubMedCrossRef

23.

Scott HR, McMillan DC, Forrest LM et al (2002) The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 87:264–267PubMedCrossRef

24.

Forrest McMillan DC, McArdle CS et al (2005) A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer 23:1834–1836CrossRef

25.

Wilop S, Crysandt M, Bendel M et al (2008) Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer. Onkologie 31:665–670PubMedCrossRef

26.

Koch A, Fohlin H, Sörenson S (2009) Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. J Thorac Oncol 4:326–332PubMedCrossRef

27.

Paesmans M, Sculier JP, Libert P et al (1995) Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 13:1221–1230PubMed

28.

Watine J (2000) Prognostic evaluation of primary non-small cell lung carcinoma patients using biological fluid variables. A systematic review. Scand J Clin Lab Invest 60:259–274PubMedCrossRef

29.

Nakahara Y, Mochiduki Y, Miyamoto Y et al (2005) Prognostic significance of the lymphocyte-to-neutrophil ratio in percutaneous fine-needle aspiration biopsy specimens of advanced nonsmall cell lung carcinoma. Cancer 104:1271–1280PubMedCrossRef

30.

Mandrekar SJ, Schild SE, Hillman SL et al (2006) A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer 15:781–792CrossRef

31.

Sarraf KM, Belcher E, Raevsky E et al (2009) Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. Thorac Cardiovasc Surg 137:425–428CrossRef

32.

Yamamoto K, Matsumoto S, Tada H et al (2008) A data capture system for outcomes studies that integrates with electronic health records: development and potential uses. J Med Syst 32:423–427PubMedCrossRef

33.

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216PubMedCrossRef

34.

Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867PubMedCrossRef

35.

Mantovani A, Allavena P, Sica A et al (2008) Cancer-related inflammation. Nature 454:436–444PubMedCrossRef

36.

Lewkowicz P, Lewkowicz N, Sasiak A, Tchorzewski H (2006) Lipopolysaccharide-activated CD4+ CD25+ T regulatory cells inhibit neutrophil function and promote their apoptosis and death. J Immunol 15:7155–7163

Titel: Difference in survival and prognostic factors between smokers and never-smokers with advanced non-small-cell lung cancer
verfasst von: Shiro Tanaka
Kazuhiro Yanagihara
Satoshi Tamaru
Satoshi Teramukai
Toshiyuki Kitano
Masanori Fukushima
Publikationsdatum: 01.02.2013
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 1/2013
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-011-0334-z

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Difference in survival and prognostic factors between smokers and never-smokers with advanced non-small-cell lung cancer